USFDA Expands Sanofi's Tzield Use to Newly Diagnosed Type 1 Diabetes Patients Aged 8-17
Bengaluru: The U.S. Food and Drug Administration said on Friday it has approved the expanded use of Sanofi's type 1 diabetes injection in children aged 8 to 17 years who were recently diagnosed with stage 3 of the condition.
The FDA had first approved the drug, Tzield, in 2022 to delay the progression of type 1 diabetes from stage 2 to 3 in patients aged 8 years and older. Its label was expanded over time.
In April, the regulator approved use of the drug to delay the progress to stage 3 in patients as young as one year.
The latest label expansion allows use of the drug in children recently diagnosed with stage 3 of the condition, with the aim of slowing down loss of insulin production.
Type 1 diabetes is a chronic condition in which the pancreas makes little or no insulin, with stage 3 patients experiencing symptoms such as frequent urination, excessive thirst and fatigue.
Stage 3 patients usually require insulin therapy to manage these symptoms.
Tzield works by targeting the immune response that damages insulin-producing cells in the pancreas, helping preserve the body's own insulin production for longer.
The latest approval was based on a study of 328 children and teenagers who had been diagnosed within the past six weeks. Patients who received the drug had a smaller decline in insulin-producing cell function than those who received a placebo after about 18 months.
Tzield, however, has been under FDA scrutiny over safety concerns. The drug has a 'boxed warning', the FDA's most prominent safety warning, after reports of serious life-threatening cases of viral infections, including Epstein-Barr virus and cytomegalovirus.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.